The ArteraAI Prostate Test is transforming the risk stratification landscape for treating localized prostate cancer. The ArteraAI Prostate Test was recently included as the first and only prognostic and predictive AI test in the NCCN Guidelines® for localized prostate cancer. Unlike genomic tests, the ArteraAI Prostate Test is a digital pathology test with a turnaround time of 2-3 days upon receipt of the biopsy slide.
During the AUA Annual Meeting 2024, Dr. Neal Shore from the Atlantic Urology Clinics, gave a presentation on the ArteraAI Prostate Test to fellow urologists. In this presentation, Dr. Shore highlights how he adopted the test for his practice and how it has impacted his patients. Watch the recorded presentation to gain insights of how the ArteraAI Prostate Test is making a difference in real-life urology practices.
Fill out the form to view the recording…
The ArteraAI Prostate Test is transforming the risk stratification landscape for treating localized prostate cancer. The ArteraAI Prostate Test was recently included as the first and only prognostic and predictive AI test in the NCCN Guidelines® for localized prostate cancer. Unlike genomic tests, the ArteraAI Prostate Test is a digital pathology test with a turnaround time of 2-3 days upon receipt of the biopsy slide.
During the AUA Annual Meeting 2024, Dr. Neal Shore from the Atlantic Urology Clinics, gave a presentation on the ArteraAI Prostate Test to fellow urologists. In this presentation, Dr. Shore highlights how he adopted the test for his practice and how it has impacted his patients. Watch the recorded presentation to gain insights of how the ArteraAI Prostate Test is making a difference in real-life urology practices.
